john burke, md, outlines the patient profile best suited for zanubrutinib in relapsed/refractory mcl
Published 4 years ago • 42 plays • Length 1:13
Download video MP4
Download video MP3
Similar videos
-
0:55
christopher yasenchak, md, tells us about the patient profile most suited for zanubrutinib in mcl
-
1:05
chaitra ujjani, md, considers the ideal patient profile for zanubrutinib in rr-mcl
-
1:08
ryan lynch, md, considers the ideal patient profile for zanubrutinib in rr-mcl
-
1:08
dr. song on zanubrutinib activity in relapsed/refractory mcl
-
1:29
dr. leslie on the role of zanubrutinib in mcl
-
2:57
selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in cll
-
41:29
2019 leslie h. blumgart historical lecture - david m nagorney md
-
17:04
episode 11 - reblozyl, brukinsa, adakveo
-
0:47
lori leslie, md, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma
-
1:22
dr. leslie on sequencing zanubrutinib in mcl
-
1:14
constantine tam, mbbs, md, regarding the patient profile in mcl most suitable for zanubrutinib
-
0:33
john burke, md, regarding gilteritinib in acute myeloid leukemia treatment
-
0:58
john burke, md, elaborates on the beat aml umbrella study
-
0:21
john burke, md, speaks to the reliability of the flt3 mutation test
-
2:00
john m. burke, md
-
0:59
dr. rule on the fda approval of zanubrutinib in mcl
-
4:40
acalabrutinib & zanubrutinib for relapsed/refractory mantle cell lymphoma - blood cancers library
-
1:03
john burke, md, offers opinion on how physicians should be thinking about the use of btk inhibitors
-
3:41
john burke, md, lists the top findings from ash 2017 regarding lymphoid malignancies
-
1:22
john burke, md, regarding tafasitamab or tafasitamab lenalidomide in addition to r-chop in dlbcl
-
5:00
beigene’s brukinsa (zanubrutinib): a newly approved treatment medicine for mantle cell lymphoma (mcl
-
1:47
john burke, md, on rituximab as an effective strategy after 1st line bendamustine-rituximab in fl
Clip.africa.com - Privacy-policy